COBRE: OK MED RES FOUND: P5: ROLE OF PROTEOGLYCAN IN ATHEROGENESIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是研究硫酸软骨素(CS)和硫酸皮肤素(DS)蛋白多糖的生物合成在动脉粥样硬化形成中的作用。当动脉粥样硬化病变在血管壁发展时，CS和DS蛋白多糖、蛋白多糖、核心蛋白多糖和魔芋多糖积聚。因为脂蛋白在体外结合到 蛋白多糖及其共定位于动脉粥样硬化病变中，已有假说认为血管壁细胞合成蛋白多糖增加是致动脉粥样硬化的原因。Biglycan是一种可能的结合和保留脂蛋白的候选蛋白多糖，因为它在体外结合致动脉粥样硬化的脂蛋白，在人类动脉粥样硬化病变中与载脂蛋白B(ApoB)和载脂蛋白E(ApoE)共存，在小鼠病变中与apoB和apoE共存比核心蛋白聚糖更紧密。此外，由于Biglycan既有蛋白质又有糖胺聚糖(GAG)介导的与其他蛋白质(例如胶原蛋白、脂蛋白、TGFbeta)的相互作用，我们假设这些相互作用对血管壁病变的结构和发展很重要。为了验证这些假说，我们的三个目标集中在三个动物模型上测量和表征动脉粥样硬化，在特定的目标1，我们将确定内皮细胞增加双聚糖的生物合成是否会夸大动脉粥样硬化的发展。在特定的目标2中，我们将确定血管平滑肌细胞增加双聚糖的生物合成是否会夸大动脉粥样硬化的发展。在特定的目标3中，我们将确定Biglycan的GAG修饰是否对动脉粥样硬化病变的发展和结构具有重要意义。所有这三种小鼠模型都将通过与低密度脂蛋白受体缺陷或载脂蛋白E缺陷小鼠杂交而形成动脉粥样硬化。我们利用这些小鼠动脉粥样硬化模型的目的是确定Biglycan的生物合成增加和GAG修饰在动脉粥样硬化病变的发生和发展中所起的作用。除了标准的动脉粥样硬化病变分析和广泛的组织学特征(包括不同胶原类型和双聚糖的免疫组织化学)外，还将使用活体显微镜和磁共振成像来表征这些小鼠的血管病理。总体而言，这些拟议的研究将更清楚地确定二聚糖积聚和二聚糖半乳糖修饰在动脉粥样硬化发病机制中的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this proposal is to investigate the role of chondroitin sulfate (CS) and dermatan sulfate (DS) proteoglycan biosynthesis in atherogenesis. As an atherosclerotic lesion develops in the blood vessel wall, CS and DS proteoglycans biglycan, decorin, and versican accumulate. Because lipoproteins bind in vitro to proteoglycans and co-localize with them in the atherosclerotic lesion, it has been hypothesized that increased proteoglycan biosynthesis by cells in the vessel wall is atherogenic. Biglycan is a likely candidate proteoglycan for binding and retaining lipoproteins since it binds atherogenic lipoproteins in vitro, colocalizes with apolipoprotein B (apoB) and E (apoE) in human atherosclerotic lesions, and more closely colocalizes with apoB and apoE in mouse lesions than decorin. Furthermore, because biglycan has both protein and glycosaminoglycan (GAG)-mediated interactions with other proteins (e.g. collagens, lipoproteins, TGFbeta), we hypothesize that these interactions are important to the structure and development of the lesion in the vascular wall. To test these hypotheses our three aims focus on measuring and characterizing atherosclerosis in 3 animal models, In specific aim 1, we will determine whether increased biosynthesis of biglycan by endothelial cells can exaggerate the development of atherosclerosis. In specific aim 2, we will determine whether increased biosynthesis of biglycan by vascular smooth muscle cells can exaggerate the development of atherosclerosis. In specific aim 3, we will determine whether the GAG modifications of biglycan are important for atherosclerotic lesion development and structure. All three mouse models will be made atherogenic by crossing them to either low-density lipoprotein receptor deficient or apolipoprotein E deficient mice. Our objectives with these mouse models of atherosclerosis are to determine the roles increased biosynthesis and GAG modification of biglycan have in atherosclerotic lesion development and progression. In addition to standard atherosclerotic lesion analysis and extensive histologic characterization including immunohistochemistry for different collagen types and biglycan, intravital microscopy and magnetic resonance imaging will be used to characterize the vascular pathology in these mice. Overall, these proposed studies will more clearly define the role biglycan accumulation and biglycan GAG modification have in the pathogenesis of atherosclerosis.